← Back to Screener
Unicycive Therapeutics, Inc. Common Stock (UNCY)
Price$7.43
Favorite Metrics
Price vs S&P 500 (26W)49.36%
Price vs S&P 500 (4W)-5.18%
Market Capitalization$177.17M
All Metrics
Book Value / Share (Quarterly)$1.37
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.42
Price vs S&P 500 (YTD)17.53%
Net Profit Margin (TTM)-4159.11%
EPS (TTM)$-2.97
10-Day Avg Trading Volume0.54M
EPS Excl Extra (TTM)$-2.97
EPS (Annual)$-5.48
Dividend / Share (Annual)$0.15
ROI (Annual)-494.27%
Cash / Share (Quarterly)$1.87
ROA (Last FY)-115.98%
EBITD / Share (TTM)$-2.95
Operating Margin (TTM)-2931.41%
Cash Flow / Share (Annual)$-1.42
P/B Ratio5.87x
P/B Ratio (Quarterly)4.11x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-1805.00x
ROA (TTM)-98.29%
EPS Incl Extra (Annual)$-5.48
Current Ratio (Annual)2.59x
Quick Ratio (Quarterly)2.18x
3-Month Avg Trading Volume0.51M
52-Week Price Return17.39%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.10
P/S Ratio (Annual)262.47x
Asset Turnover (Annual)0.05x
52-Week High$11.00
EPS Excl Extra (Annual)$-5.48
26-Week Price Return58.11%
Quick Ratio (Annual)2.18x
13-Week Price Return6.20%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.59x
Enterprise Value$147.971
Asset Turnover (TTM)0.05x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-4525.04%
Cash / Share (Annual)$1.87
3-Month Return Std Dev67.47%
Net Income / Employee (TTM)$-1
ROE (Last FY)-494.27%
Net Interest Coverage (Annual)-9.30x
EPS Basic Excl Extra (Annual)$-5.48
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.97
ROI (TTM)-200.05%
P/S Ratio (TTM)31.15x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$-0.03
Forward P/E114.05x
Price vs S&P 500 (52W)-17.70%
Year-to-Date Return21.66%
5-Day Price Return6.04%
EPS Normalized (Annual)$-5.48
ROA (5Y Avg)-431.02%
Net Profit Margin (Annual)-4525.04%
Month-to-Date Return6.69%
Cash Flow / Share (TTM)$-1.48
EBITD / Share (Annual)$-5.66
Operating Margin (Annual)-3077.63%
EPS Basic Excl Extra (TTM)$-2.97
P/TBV (Quarterly)6.12x
P/B Ratio (Annual)4.11x
Pretax Margin (TTM)-4159.11%
Book Value / Share (Annual)$1.37
Price vs S&P 500 (13W)3.34%
Beta1.66x
Revenue / Share (TTM)$0.00
ROE (TTM)-200.05%
52-Week Low$3.71
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
UNCYUnicycive Therapeutics, Inc. Common Stock | 31.15x | — | — | — | $7.43 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Unicycive Therapeutics is a biotechnology company developing novel therapies for kidney diseases. Its lead programs include Renazorb, a phosphate-binding agent in development for hyperphosphatemia, and UNI-494, an investigational therapy in late preclinical development for acute kidney injury.